Johnson & Johnson (JNJ) Debt to Equity Ratio: 0.59
Is Johnson & Johnson’s debt to equity ratio high or low?
Johnson & Johnson's debt to equity ratio of 0.59 is 15% above its 5-year average of 0.51, near the high end of its 5-year range (0.43–0.59).
The debt to equity ratio for Johnson & Johnson (JNJ) is 0.59 as of Tuesday, June 9, 2026. It is above its 12-month average by 7.27% (0.55).
JNJ Debt to Equity Ratio Chart
JNJ Average Debt to Equity Ratio Chart
JNJ Current vs Average Debt to Equity Ratio Chart
JNJ Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.59
DEBT TO EQUITY RATIO AVG TTM
0.55
DEBT TO EQUITY RATIO AVG 3Y
0.51
DEBT TO EQUITY RATIO AVG 5Y
0.51
DEBT TO EQUITY RATIO AVG 10Y
0.48
DEBT TO EQUITY RATIO AVG 15Y
0.42
DEBT TO EQUITY RATIO AVG 20Y
0.37
CURRENT VS TTM AVG
+7.27%
CURRENT VS 3Y AVG
+15.12%
CURRENT VS 5Y AVG
+15.31%
CURRENT VS 10Y AVG
+22.68%
CURRENT VS 15Y AVG
+40.90%
CURRENT VS 20Y AVG
+60.28%
JNJ Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | — | 0.59 | 0.55 | 0.51 | 0.51 |
| Pfizer Inc. (PFE) | $146.48B | 0.78 | 0.77 | 0.68 | 0.63 |
| Merck & Co., Inc. (MRK) | $295.39B | 0.96 | 0.90 | 0.86 | 0.95 |
| AbbVie Inc. (ABBV) | $398.27B | -21.12 | 13.10 | 8.74 | 8.32 |
| Eli Lilly and Company (LLY) | $1.08T | 1.60 | 1.99 | 1.96 | 2.11 |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 2.55 | 2.84 | 2.10 | 1.84 |
Financial Health
Debt/Equity
0.59
Current Ratio
1.03
Johnson & Johnson Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Johnson & Johnson (JNJ)?
- The debt to equity ratio for JNJ stock is 0.59.
- Is Johnson & Johnson's debt to equity ratio high or low?
- Johnson & Johnson's debt to equity ratio of 0.59 is 15% above its 5-year average of 0.51, near the high end of its 5-year range (0.43–0.59).
- What is the TTM average debt to equity ratio for Johnson & Johnson (JNJ)?
- The TTM average debt to equity ratio for JNJ stock is 0.55.
- What is the 3Y average debt to equity ratio for Johnson & Johnson (JNJ)?
- The 3Y average debt to equity ratio for JNJ stock is 0.51.
- What is the 5Y average debt to equity ratio for Johnson & Johnson (JNJ)?
- The 5Y average debt to equity ratio for JNJ stock is 0.51.
- What is the 10Y average debt to equity ratio for Johnson & Johnson (JNJ)?
- The 10Y average debt to equity ratio for JNJ stock is 0.48.
- What is the 15Y average debt to equity ratio for Johnson & Johnson (JNJ)?
- The 15Y average debt to equity ratio for JNJ stock is 0.42.
- What is the 20Y average debt to equity ratio for Johnson & Johnson (JNJ)?
- The 20Y average debt to equity ratio for JNJ stock is 0.37.
Johnson & Johnson Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-28 | 0.59 |
| 2024-12-29 | 0.51 |
| 2023-12-31 | 0.43 |
| 2023-01-01 | 0.52 |
| 2022-01-02 | 0.46 |
| 2021-01-03 | 0.56 |
| 2019-12-31 | 0.47 |
| 2018-12-31 | 0.51 |
| 2017-12-31 | 0.57 |
| 2016-12-31 | 0.39 |
| 2015-12-31 | 0.28 |
| 2014-12-31 | 0.27 |
| 2013-12-31 | 0.25 |
| 2012-12-31 | 0.25 |
| 2011-12-31 | 0.34 |
| 2010-12-31 | 0.30 |
| 2009-12-31 | 0.29 |
| 2008-12-31 | 0.28 |
| 2007-12-31 | 0.22 |
| 2006-12-31 | 0.17 |
| 2005-12-31 | 0.07 |
| 2004-12-31 | 0.09 |
| 2003-12-31 | 0.15 |
| 2002-12-31 | 0.18 |
| 2001-12-31 | 0.11 |
| 2000-12-31 | 0.23 |
| 1999-12-31 | 0.26 |
| 1998-12-31 | 0.32 |
| 1997-12-31 | 0.15 |
| 1996-12-31 | 0.21 |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato